Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValirx Share News (VAL)

Share Price Information for Valirx (VAL)

London Stock Exchange
Share Price: 0.135
Bid: 0.13
Ask: 0.14
Change: 0.00 (0.00%)
Spread: 0.01 (7.69%)
Open: 0.135
High: 0.135
Low: 0.135
Yest. Close: 0.135
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

CORRECT: ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

15 Nov 13 12:39

UK WINNERS & LOSERS: IAG Dives Despite Raising Profit Guidance

15 Nov 13 12:37

ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

15 Nov 13 10:28

AIM IN BRIEF: Quindell And ValiRx Placings; Noricum Gold Positive Results

15 Nov 13 07:53

ValiRx Anti-Cancer Treatment Advances To Phase 2 Of Clinical Trial

24 Oct 13 15:48

UK WINNERS & LOSERS: Phorm Jumps; Supermarkets Rebound

3 Oct 13 11:39

ValiRx Cancer Treatment Files Escalation Study

3 Oct 13 08:08

ValiRX reports encouraging progress despite losses

ValiRx, a biopharmaceutial company with a focus on the treatment of cancer, said while losses had widened in the first half it had made "excellent" advances in its clinical and pre-clinical development pipeline. It reiterated that it expected results from the first stage of clinical trials for its

5 Sep 13 11:44

ValiRx Losses Widen But Says Compounds Progressing In Trials

5 Sep 13 09:20

ValiRx granted patent in Australia for VAL201 targeting cancer

ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia. The cancer diagnostics company said VAL201 has shown efficacy in prostate, breast and ovarian cancer as well as addressing endometriosis or hormon

25 Apr 13 10:02

ValiRx to present at key Cancer Conference

Shares in life science company ValiRx rose on Tuesday morning after the AIM-listed company announced that it would be presenting at the American Association for Cancer Research Conference this year. The conference, which was attended by approximately 17,000 delegates last year, is seen as a key eve

2 Apr 13 08:41

ValiRx appoints COO to help build portfolio

Biotech firm ValiRx has appointed a Chief Operating Officer to assist in building and adding value to its portfolio of technologies and to coordinate ValiRx's commercial strategy. Samual Ogunsalu has a background in Microbiology and Biochemical engineering and has 15 years' experience in the identi

21 Feb 13 13:17

Small cap round-up: InterQuest, ValiRx, Aeorema Comms

InterQuest has warned that trading during the summer, traditionally its strongest period, has been sluggish. As a result underlying earnings before interest, tax, depreciation and amortisation (EBITDA) will be in the region of 2.2m pounds. This does not include an exceptional credit of about 0.85m p

22 Nov 12 15:56

Contract wins round-up: LO-Q, Motive TV, Plexus ...

Lo-Q has announced its second contract win of the week, as an unnamed major US theme park operator has signed up to use the firm's virtual queueing system at two sites in the US. Revenue associated with the agreement is expected to scale gradually, over time. In addition, the deal grants that Lo-Q's

11 Oct 12 09:50

Small cap round-up: ValiRx, Transense, Sweett

Shares in ValiRx, the life sciences firm, leapt almost 40% on Tuesday after it said independent trials had confirmed the effectiveness of its prostate cancer drug VAL201. The firm said the "significant and substantively important findings" showed its drug reduced the spread of secondary tumours by u

29 May 12 08:37

Login to your account

Don't have an account? Click here to register.